Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib, second-line pancreatic cancer treatment, 'truly remarkable' | 2026 ASCO
2
A conversation about the challenges and benefits of HIV testing in church, with Jannette Berkley-Patton, Ph.D., and Kathryn Derose, Ph.D.
3
Daraxonrasib's MOA: It is a sticky business | ASCO 2026
4
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
5